Skip to content
Screener

Alnylam Pharmaceuticals ALNY EV / EBITDA

EV / EBITDA at other companies

Arrowhead Research logo
Arrowhead ResearchARWR
27.4×—
PTC Therapeutics logo
PTC TherapeuticsPTCT
86.6×+82.7×
Arbutus Biopharma Corporation logo
Arbutus Biopharma CorporationABUS
5.5×—
ANI Pharmaceuticals logo
ANI PharmaceuticalsANIP
8.1×-16.2×
Mirum Pharmaceuticals, Inc. logo
Mirum Pharmaceuticals, Inc.MIRM
1,820.6×—

Other financials

Income statement

See full
Revenue$1.3B+66.9%
Gross profit$992.7M+57.2%
Operating income$231.4M+1,529%
Net income$164.5M+348%
EPS (diluted)$1.21+337%

Balance sheet

See full
Cash & equivalents$1.7B+53.2%
Total debt$256.4M-5.2%
Total equity$1.4B+440%
Total assets$5.6B+21.7%

Cash flow

See full
Operating cash flow$326.7M+113%
CapEx$34.7M+143%
Free cash flow$292.0M+109%

Valuation

See full
Market cap$27.5B-50.0%
Enterprise value$26.05B-51.9%
P/E37.5×—
P/S5.7×-16.6×

Profitability

See full
Gross margin79.8%-4.1pp
Operating margin20.8%+16.5pp
Net margin15.3%+10.7pp
FCF margin16.5%+14.8pp

Returns & leverage

See full
Return on equity91.4%—
Debt / equity0.2×-0.9×
Current ratio3.1×+0.3×

Where this comes from

Calculated from Alnylam Pharmaceuticals’s reported figures.

enterprise value/ebitda=36.7×

Based on the most recent quarter.

The source filing: Alnylam Pharmaceuticals’s 10-Q, filed July 30, 2026. Open the filing →

Filed
Jul 30, 2026, 8:11 AM EDT
Fiscal quarter
Q2 FY2026
Calendar quarter
Q2 2026
Accession
0001178670-26-000062

FAQ

What is Alnylam Pharmaceuticals's EV / EBITDA?
Alnylam Pharmaceuticals (ALNY) reported EV / EBITDA of 36.7× in Q2 2026.
What does EV / EBITDA mean?
Enterprise value (market cap plus total debt minus cash) at the quarter end divided by trailing-twelve-month EBITDA. A capital-structure-neutral valuation multiple.

Ask your AI about Alnylam Pharmaceuticals's ev / ebitda.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude